SVS Stock Overview
SVAS Biosana S.p.A. engages in the production and marketing of medical devices worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Svas Biosana S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.95 |
| 52 Week High | €9.80 |
| 52 Week Low | €6.90 |
| Beta | 0.93 |
| 1 Month Change | -4.90% |
| 3 Month Change | 5.72% |
| 1 Year Change | -11.86% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -45.13% |
Recent News & Updates
Shareholder Returns
| SVS | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | -2.5% | 4.3% | -1.4% |
| 1Y | -11.9% | 2.9% | 15.8% |
Return vs Industry: SVS underperformed the Italian Medical Equipment industry which returned 2.9% over the past year.
Return vs Market: SVS underperformed the Italian Market which returned 15.8% over the past year.
Price Volatility
| SVS volatility | |
|---|---|
| SVS Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IT Market | 7.5% |
| 10% least volatile stocks in IT Market | 2.7% |
Stable Share Price: SVS has not had significant price volatility in the past 3 months.
Volatility Over Time: SVS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 374 | Umberto Perillo | svas.it |
SVAS Biosana S.p.A. engages in the production and marketing of medical devices worldwide. The company offers incontinence aids, traditional dressings, and personal care products for use in incontinence devices, dressings, and personal care product applications. It also offers operating packs, medical devices, infusion and aspiration, linen, advanced dressings, and lubricating gels that are used in haemodynamic, heart surgery, anaesthesia, and critical care applications.
Svas Biosana S.p.A. Fundamentals Summary
| SVS fundamental statistics | |
|---|---|
| Market cap | €42.92m |
| Earnings (TTM) | €4.14m |
| Revenue (TTM) | €111.70m |
10.4x
P/E Ratio0.4x
P/S RatioIs SVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVS income statement (TTM) | |
|---|---|
| Revenue | €111.70m |
| Cost of Revenue | €82.40m |
| Gross Profit | €29.30m |
| Other Expenses | €25.16m |
| Earnings | €4.14m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.77 |
| Gross Margin | 26.23% |
| Net Profit Margin | 3.71% |
| Debt/Equity Ratio | 95.9% |
How did SVS perform over the long term?
See historical performance and comparison